Two further clinical trials are also currently underway utilising NIS as both a reporter for virus tracking in patients with multiple myeloma, and for gene therapy of prostate cancer in conjunction with radioiodine (Clinicaltrials.gov). Here, SLC5A5 is linked to plasma cell myeloma.